Reason: Surrendered license voluntarily.

License Number: 015646N.

Name: Universe Freight Brokers, Inc. dba Seacarriers.

Address: 3625 NW. 82nd Avenue, Suite 401, Miami, FL 33126.

Date Revoked: October 30, 2004.

Reason: Failed to maintain a valid bond.

Sandra L. Kusumoto,

Director, Bureau of Certification and Licensing.

[FR Doc. 04–27441 Filed 12–14–04; 8:45 am]

BILLING CODE 6730–01–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than December 29, 2004.

A. Federal Reserve Bank of Atlanta (Sue Costello, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. Evan R. Marbin, North Miami Beach, Florida, individually and as trustee of The SEE Trust, Miami, Florida, The SEE Trust, Miami, Florida, and Sherrie Marbin, North Miami Beach, Florida, to retain voting shares of Transatlantic Bank, Miami, Florida.

B. Federal Reserve Bank of Kansas City (Donna J. Ward, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198–0001:

1. Charles W. Masner and Ella C. Masner, both of Anthony, Kansas; to acquire control of Olathe Bancorporation, Inc., and thereby indirectly acquire control of Olathe State Bank, both in Olathe, Colorado.

Board of Governors of the Federal Reserve System, December 9, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–27475 Filed 12–14–04; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at *www.ffiec.gov/nic/*.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 10, 2005.

A. Federal Reserve Bank of Chicago (Patrick Wilder, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. American Central Bancorporation, Inc., Springfield, Illinois; to merge with American Central Financial Group, Inc., Springfield, Illinois, and thereby indirectly acquire Farmers State Bank of Fulton County, Lewistown, Illinois, and The Bank, Charleston, Illinois.

Board of Governors of the Federal Reserve System, December 9, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–27476 Filed 12–14–04; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 2003M–0172, 2004M–0309, 2004M–0433, 2004M–0341, 2004M–0356, 2004M–0403, 2004M–0310, 2004M–0312, 2004M–0313, 2004M–0342, 2004M–0323, 2004M–0345, 2004M–0350, 2004M–0387, 2004M–0415, 2004M–0388, and 2004M–0430]

Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the agency's Division of Dockets Management.

ADDRESSES: Submit written requests for copies of summaries of safety and effectiveness to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 of this document when submitting a written request. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the summaries of safety and effectiveness.

FOR FURTHER INFORMATION CONTACT: Thinh Nguyen, Center for Devices and Radiological Health (HFZ–402), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2186.

SUPPLEMENTARY INFORMATION:

I. Background

In the Federal Register of January 30, 1998 (63 FR 4571), FDA published a final rule that revised 21 CFR 814.44(d) and 814.45(d) to discontinue individual publication of PMA approvals and denials in the **Federal Register**. Instead, the agency now posts this information on the Internet on FDA's home page at *http://www.fda.gov*. FDA believes that this procedure expedites public

notification of these actions because announcements can be placed on the Internet more quickly than they can be published in the **Federal Register**, and FDA believes that the Internet is accessible to more people than the **Federal Register**.

In accordance with section 515(d)(4) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from July 1, 2004, through September 30, 2004. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.

TABLE 1.—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JULY 1, 2004, THROUGH SEPTEMBER 30, 2004

PMA No./Docket No.	Applicant	Trade Name	Approval Date
P020026/2003M–0172	Cordis Corp.	CYPHER SIROLIMUS-ELUTING CORONARY STENT ON THE RAPTOR OVER-THE-WIRE DELIVERY SYSTEM OR RAPTORRAIL RAPID EXCHANGE DELIVERY SYSTEM	April 24, 2003
P020023/2004M–0309	Q-Med Scandinavia, Inc.	RESTYLANE INJECTABLE GEL	December 12, 2003
P030044/2004M–0433	DakoCytomation California, Inc.	DAKOCYTOMATION EGFR PHARMDX	February 12, 2004
P030024/2004M–0341	Ortho-Clinical Diagnostics, Inc.	VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBC REAGENT PACK AND CALIBRATOR	March 4, 2004
P030026/2004M–0356	Ortho-Clinical Diagnostics, Inc.	VITROS IMMUNODIAGOSTIC PRODUCTS ANTI-HBC IGM REAGENT PACK AND CALIBRATOR	March 4, 2004
P030025/2004M–0403	Boston Scientific Corp.	TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEM (MONORAIL AND OVER-THE-WIRE)	March 4, 2004
P020030/2004M–0310	Ela Medical, Inc.	STELID II/STELIX/STELIX II ENDOCARDIAL PACING LEAD	June 17, 2004
P970043 (S015)/2004M–0312	Alcon Laboratories, Inc.	LADARVISION 4000 EXCIMER LASER SYSTEM	June 29, 2004
P030054/2004M–0313	St. Jude Medical, Inc.	ST. JUDE MEDICAL EPIC HF SYSTEM	June 30, 2004
P040008/2004M–0342	bioMerieux, Inc.	VIDAS TPSA ASSAY	July 8, 2004
P030012/2004M–0323	R2 Technology, Inc.	IMAGECHECKER CT CAD SOFTWARE SYSTEM (MODEL LN–1000)	July 8, 2004
P010061/2004M–0345	Photo Cure, ASA	CURELIGHT BROADBAND (MODEL CURELIGHT 01)	July 28, 2004
P030050/2004M–0350	Dermik Laboratories	SCULPTRA	August 3, 2004
P030010/2004M–0387	Siemens Medical Solutions USA, Inc.	SIEMENS MAMMOMAT NOVATIONDR FULL FIELD DIGITAL MAMMOGRAPHY SYSTEM	August 20, 2004
H030009/2004M–0415	Synthes (USA)	VERTICAL EXPANDABLE PROSTHETIC TITANIUM RIB (VEPTR)	August 24, 2004
P040012/2004M–0388	Guidant Corp.	ACULINK CAROTID STENT SYSTEM & RX ACCULINK CAROTID STENT SYSTEM	August 30, 2004
P010012 (S026)/2004M–0430	Guidant Corp.	CONTAK CD (MODEL 1823), CONTAK CD 2 (MODELS H115 & H119), RENEWAL (MODEL H135), RENEWAL 3 (MODELS H170, H175, H177, & H179)	September 14, 2004

II. Electronic Access

Persons with access to the Internet may obtain the documents at *http://www.fda.gov/cdrh/pmapage.html.*

Dated: December 3, 2004.

Linda S. Kahan,

Deputy Director, Center for Devices and Radiological Health.

[FR Doc. 04–27387 Filed 12–14–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), notice is hereby given of the following meeting:

Name: Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children (ACHDGDNC).

Dates and Times: January 13, 2005, 9 a.m. to 5 p.m. January 14, 2005, 9 a.m. to 5 p.m.

Place: Ronald Reagan Building and International Trade Center, 1300 Pennsylvania Avenue, NW., Washington, DC 20004.

Status: The meeting will be open to the public with attendance limited to space availability.

Purpose: The Advisory Committee provides advice and recommendations concerning the grants and projects authorized under the Heritable Disorders Program and technical information to develop policies and priorities for this program that will enhance the ability of State and local health agencies to provide for newborn and child screening, counseling and health care services for newborns and children having or at risk for heritable disorders. Specifically, the Committee shall advise and guide the Secretary regarding the most appropriate application of universal newborn screening tests, technologies, policies, guidelines and programs for effectively reducing morbidity and mortality in newborns and children having or at risk for heritable disorders.

Agenda: The first day will be devoted to presentations on and a discussion of the status of the report from the American College of Medical Genetics; an update of the current status of state specific issues; presentations on the Rare Disease Centers of Excellence funded by the National Institutes of Health and the Regional Genetics; and Newborn Screening Collaboratives funded by the Health Resources and Services Administration. The presentations will be followed on the first and second day with more detailed discussions aimed at formulating the ACHDGDNC issues agenda.

Proposed agenda items are subject to change.

Time will be provided each day for public comment. Individuals who wish to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the ACHDGDNC Executive Secretary, Michele A. Lloyd-Puryear, M.D., Ph.D. (contact information provided below).

Contact Person: Anyone interested in obtaining a roster of members or other relevant information should write or contact Michele A. Lloyd-Puryear, M.D., Ph.D., Maternal and Child Health Bureau, Health Resources and Services Administration, Room 18A–19, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–1080. Information on the Advisory Committee is available at *http://mchb.hrsa.gov/programs/genetics/committee.*

Dated: December 8, 2004.

Tina M. Cheatham,

Director, Division of Policy Review and Coordination.

[FR Doc. 04–27388 Filed 12–14–04; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President's Cancer Panel.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended, because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

Name of Committee: President's Cancer Panel.

Date: January 24–25, 2005.

Open: January 24, 2005, 8 a.m. to 4 p.m.

Agenda: Translating Research to Reduce Burden of Cancer.

Place: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Closed: January 25, 2005, 9 a.m. to 12 p.m.

Agenda: The Panel will supplement its public hearings with discussion of prepublication manuscripts on Translating Research into Clinical Practice. These manuscripts have been provided by their authors with the understanding that the Panel will not break prepublication embargo conditions.

Place: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Contact Person: Maureen O. Wilson, PhD, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A18, Bethesda, MD 20892, 301/496–1148.

Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: *deainfo.nci.nih.gov/advisory/pcp/pcp.htm,* where an agenda and any additional information for the meeting will be posed when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: December 6, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04–27407 Filed 12–14–04; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel